RGS17

Summary

RGS17 (regulator of G protein signaling 17, HGNC:14088) is a protein-coding gene on chromosome 6q25.2, encoding Regulator of G-protein signaling 17 (Q9UGC6). Regulates G protein-coupled receptor signaling cascades, including signaling via muscarinic acetylcholine receptor CHRM2 and dopamine receptor DRD2.

This gene encodes a member of the regulator of G-protein signaling family. This protein contains a conserved, 120 amino acid motif called the RGS domain and a cysteine-rich region. The protein attenuates the signaling activity of G-proteins by binding to activated, GTP-bound G alpha subunits and acting as a GTPase activating protein (GAP), increasing the rate of conversion of the GTP to GDP. This hydrolysis allows the G alpha subunits to bind G beta/gamma subunit heterodimers, forming inactive G-protein heterotrimers, thereby terminating the signal.

Source: NCBI Gene 26575 — RefSeq curated summary.

At a glance

• GWAS associations: 19
• Clinical variants (ClinVar): 20 total
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_012419

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14088
Approved symbol	RGS17
Name	regulator of G protein signaling 17
Location	6q25.2
Locus type	gene with protein product
Status	Approved
Aliases	RGSZ2, RGS-17
Ensembl gene	ENSG00000091844
Ensembl biotype	protein_coding
OMIM	607191
Entrez	26575

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000206262, ENST00000367225, ENST00000914255

RefSeq mRNA: 1 — MANE Select: NM_012419 NM_012419

CCDS: CCDS5244

Canonical transcript exons

ENST00000206262 — 5 exons

Exon	Start	End
ENSE00001240271	153131124	153131282
ENSE00003890589	153024262	153024496
ENSE00003891788	153004459	153011762
ENSE00003894299	153043900	153044043
ENSE00003895490	153026454	153026543

Expression profiles

Bgee: expression breadth ubiquitous, 227 present calls, max score 86.43.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.7485 / max 101.8326, expressed in 1130 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
76275	4.7485	1130

Top tissues by expression

260 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	86.43	gold quality
buccal mucosa cell	CL:0002336	84.72	gold quality
tendon of biceps brachii	UBERON:0008188	83.69	gold quality
cartilage tissue	UBERON:0002418	82.00	gold quality
middle temporal gyrus	UBERON:0002771	78.24	gold quality
islet of Langerhans	UBERON:0000006	77.61	gold quality
ganglionic eminence	UBERON:0004023	76.19	gold quality
Brodmann (1909) area 23	UBERON:0013554	75.24	gold quality
mucosa of paranasal sinus	UBERON:0005030	75.14	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	74.54	gold quality
pancreatic ductal cell	CL:0002079	74.54	silver quality
amniotic fluid	UBERON:0000173	74.20	gold quality
Brodmann (1909) area 46	UBERON:0006483	73.72	gold quality
cerebellar vermis	UBERON:0004720	73.58	gold quality
entorhinal cortex	UBERON:0002728	72.80	gold quality
ventricular zone	UBERON:0003053	72.69	gold quality
cerebellum	UBERON:0002037	72.54	gold quality
cerebellar cortex	UBERON:0002129	72.35	gold quality
cerebellar hemisphere	UBERON:0002245	72.22	gold quality
superior frontal gyrus	UBERON:0002661	71.93	gold quality
sperm	CL:0000019	71.20	silver quality
right hemisphere of cerebellum	UBERON:0014890	71.16	gold quality
postcentral gyrus	UBERON:0002581	71.12	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	70.42	gold quality
parietal lobe	UBERON:0001872	70.07	gold quality
embryo	UBERON:0000922	70.02	gold quality
primary visual cortex	UBERON:0002436	69.90	gold quality
male germ cell	CL:0000015	69.54	silver quality
prefrontal cortex	UBERON:0000451	69.30	gold quality
tendon	UBERON:0000043	68.45	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.05

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

78 targeting RGS17, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-129-5P	99.88	70.26	3273

Literature-anchored findings (GeneRIF, showing 16)

• RGS17 is a new RZ member that preferentially inhibits receptor signaling via G(i/o), G(z), and G(q) over G(s) to enhance cAMP-dependent signaling and inhibit calcium signaling (PMID:15096504)
• RGS17, an overexpressed gene in human lung and prostate cancer, induces tumor cell proliferation through the cyclic AMP-PKA-CREB pathway. (PMID:19244110)
• RGS17 is a major candidate for the familial lung cancer susceptibility locus on chromosome 6q23-25. (PMID:19351763)
• Taken together, these data have provided the first evidence of miRNA regulation of RGS17 expression in lung cancer. (PMID:20420807)
• Results establish RGS10 and RGS17 as novel regulators of cell survival and chemoresistance in ovarian cancer cells and suggest that their reduced expression may be diagnostic of chemoresistance. (PMID:21044322)
• RGS17 is differentially expressed in hepatocellular carcinoma cells and plays a central role in regulating transformed hepatocyte tumorgenicity. (PMID:21620966)
• Two single nucleotide polymorphisms in the regulator of G-protein signaling 17 gene are associated with smoking initiation. (PMID:22006218)
• Variation in RGS17 was associated with risk for substance dependence diagnoses in both African American and European American populations. (PMID:22591552)
• data suggest that RGS17 is overexpressed in colorectal carcinoma and promotes cell proliferation, migration, and invasion (PMID:28337960)
• Taken together, the results suggested that expression of miR-203 inhibited non-small-cell lung cancer tumor growth and metastasis by targeting RGS17 (PMID:28921827)
• A screen of over 60,000 small molecules led to the identification of five hit compounds that inhibit the RGS17-Galphao protein-protein interaction. (PMID:29351497)
• Results showed that RGS17 overexpression promoted hepatocarcinoma (HCC) cell proliferation, migration, and invasion, and reversed the miR-199 mediated inhibition of proliferation, migration, and invasion. (PMID:29559347)
• these findings suggest that Ca(2+) positively regulates RGS17, which may represent a general mechanism by which increased Ca(2+) concentration promotes the GAP activity of the RZ subfamily, leading to RZ-mediated inhibition of Ca(2+) signaling. (PMID:30940727)
• Knock-down of Long non-coding RNA Linc00483 inhibited the development of cervical cancer by regulating miR-508-3p/RGS17 axis. (PMID:31454494)
• MiR-203 inhibits cell proliferation, invasion, and migration of ovarian cancer through regulating RGS17. (PMID:34002599)
• Hsa_circ_0000285-Mediated miR-599/RGS17 Axis Participates in the Pathogenesis of Abdominal Aortic Aneurysm by Regulating the Functions of Vascular Smooth Muscle Cells. (PMID:37094862)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	rgs17	ENSDARG00000039435
mus_musculus	Rgs17	ENSMUSG00000019775
rattus_norvegicus	Rgs17	ENSRNOG00000018690
drosophila_melanogaster	Dhit	FBGN0028743

Paralogs (23): RGS11 (ENSG00000076344), RGS1 (ENSG00000090104), AXIN1 (ENSG00000103126), RGS9 (ENSG00000108370), RGS2 (ENSG00000116741), RGS4 (ENSG00000117152), RGSL1 (ENSG00000121446), RGS13 (ENSG00000127074), RGS22 (ENSG00000132554), RGS8 (ENSG00000135824), RGS3 (ENSG00000138835), RGS5 (ENSG00000143248), RGS16 (ENSG00000143333), RGS20 (ENSG00000147509), RGS10 (ENSG00000148908), RGS18 (ENSG00000150681), RGS12 (ENSG00000159788), AXIN2 (ENSG00000168646), RGS14 (ENSG00000169220), RGS19 (ENSG00000171700), RGS6 (ENSG00000182732), RGS7 (ENSG00000182901), RGS21 (ENSG00000253148)

Protein

Protein identifiers

Regulator of G-protein signaling 17 — Q9UGC6 (reviewed: Q9UGC6)

All UniProt accessions (1): Q9UGC6

UniProt curated annotations — full annotation on UniProt →

Function. Regulates G protein-coupled receptor signaling cascades, including signaling via muscarinic acetylcholine receptor CHRM2 and dopamine receptor DRD2. Inhibits signal transduction by increasing the GTPase activity of G protein alpha subunits, thereby driving them into their inactive GDP-bound form. Binds selectively to GNAZ and GNAI2 subunits, accelerates their GTPase activity and regulates their signaling activities. Negatively regulates mu-opioid receptor-mediated activation of the G-proteins.

Subunit / interactions. Interacts with GNAI1 and GNAQ. Interacts with GNAZ and GNAI2. Interacts with OPRM1. Forms a complex with mu-opioid receptors and G(alpha)z/i2 subunits, including GNAZ and GNAI2; the formation of this complex results in mu-opioid receptor desensitization. Interacts with HINT1.

Subcellular location. Membrane. Synapse. Synaptosome. Nucleus. Cytoplasm.

Tissue specificity. Predominantly expressed in the cerebellum. Also expressed in the cortex and medulla. Weakly expressed in a number of peripheral tissues notably spleen, lung and leukocytes.

Post-translational modifications. N- and O-glycosylated in synapsomal membranes. Serine phosphorylated in synapsomal membranes. Sumoylated with SUMO1 and SUM02 in synaptosomes. The sumoylated forms act as a scaffold for sequestering mu-opioid receptor-activated G(alpha) subunits. Desumoylated by HINT1.

RefSeq proteins (1): NP_036551* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016137	RGS	Domain
IPR036305	RGS_sf	Homologous_superfamily
IPR044926	RGS_subdomain_2	Homologous_superfamily

Pfam: PF00615

UniProt features (15 total): helix 10, chain 1, domain 1, turn 1, region of interest 1, modified residue 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
6AM3	X-RAY DIFFRACTION	1.53
1ZV4	X-RAY DIFFRACTION	2.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UGC6-F1	79.82	0.64

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 137

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-416476	G alpha (q) signalling events
R-HSA-418594	G alpha (i) signalling events
R-HSA-418597	G alpha (z) signalling events

MSigDB gene sets: 150 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, RNGTGGGC_UNKNOWN, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_RESPONSE_TO_AMINE, REACTOME_G_ALPHA_Z_SIGNALLING_EVENTS, AAAYRNCTG_UNKNOWN, chr6q25, GOBP_RESPONSE_TO_AMPHETAMINE, DELYS_THYROID_CANCER_DN, ONDER_CDH1_TARGETS_2_UP, YAMASHITA_METHYLATED_IN_PROSTATE_CANCER, GOCC_NEURON_PROJECTION, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, CUI_TCF21_TARGETS_2_UP

GO Biological Process (3): response to amphetamine (GO:0001975), G protein-coupled receptor signaling pathway (GO:0007186), negative regulation of signal transduction (GO:0009968)

GO Molecular Function (3): GTPase activity (GO:0003924), GTPase activator activity (GO:0005096), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), cytoplasm (GO:0005737), plasma membrane (GO:0005886), neuron projection (GO:0043005), synapse (GO:0045202), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
GPCR downstream signalling	3

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
signal transduction	2
cellular anatomical structure	2
response to amine	1
G protein-coupled receptor activity	1
regulation of signal transduction	1
negative regulation of cell communication	1
negative regulation of signaling	1
negative regulation of response to stimulus	1
ribonucleoside triphosphate phosphatase activity	1
GTPase activity	1
enzyme activator activity	1
GTPase regulator activity	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
plasma membrane bounded cell projection	1
cell junction	1

Protein interactions and networks

STRING

1296 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RGS17	GNB5	O14775	878
RGS17	SUCLG2	Q96I99	853
RGS17	GNAQ	P50148	789
RGS17	ARHGEF1	Q92888	788
RGS17	ARHGEF11	O15085	785
RGS17	RGSL1	A5PLK6	776
RGS17	GRK2	P25098	770
RGS17	RGS7BP	Q6MZT1	725
RGS17	MCF2	P10911	707
RGS17	GNA13	Q14344	707
RGS17	SUCLG1	P53597	695
RGS17	PLEK	P08567	689
RGS17	AKAP10	O43572	671
RGS17	PLEK2	Q9NYT0	668
RGS17	ARHGEF25	Q86VW2	664

IntAct

156 interactions, top by confidence:

A	B	Type	Score
RGS17	AQP1	psi-mi:“MI:0915”(physical association)	0.720
OTX1	RGS17	psi-mi:“MI:0915”(physical association)	0.720
RGS17	HOXA1	psi-mi:“MI:0915”(physical association)	0.720
RPL10A	RGS17	psi-mi:“MI:0915”(physical association)	0.720
AQP1	RGS17	psi-mi:“MI:0915”(physical association)	0.720
RGS17	OTX1	psi-mi:“MI:0915”(physical association)	0.720
RGS17	RPL10A	psi-mi:“MI:0915”(physical association)	0.720
HOXA1	RGS17	psi-mi:“MI:0915”(physical association)	0.720
NUFIP2	RGS17	psi-mi:“MI:0915”(physical association)	0.560
RGS17	GNAI3	psi-mi:“MI:0915”(physical association)	0.560
SMCP	RGS17	psi-mi:“MI:0915”(physical association)	0.560
GNAI1	RGS17	psi-mi:“MI:0915”(physical association)	0.560
PTGER3	RGS17	psi-mi:“MI:0915”(physical association)	0.560
RGS17	LCE3C	psi-mi:“MI:0915”(physical association)	0.560
RGS17	LCE4A	psi-mi:“MI:0915”(physical association)	0.560
RGS17	LCE2A	psi-mi:“MI:0915”(physical association)	0.560
	RGS17	psi-mi:“MI:0915”(physical association)	0.560
RGS17		psi-mi:“MI:0915”(physical association)	0.560
RGS17	NUFIP2	psi-mi:“MI:0915”(physical association)	0.560
RGS17	GNAI1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (52): RGS17 (Two-hybrid), RGS17 (Two-hybrid), RGS17 (Two-hybrid), RGS17 (Two-hybrid), RGS17 (Two-hybrid), RGS17 (Two-hybrid), RGS17 (Two-hybrid), RGS17 (Two-hybrid), NUFIP2 (Two-hybrid), DHX37 (Two-hybrid), TBC1D16 (Two-hybrid), LCE4A (Two-hybrid), LCE2A (Two-hybrid), LCE3C (Two-hybrid), RGS17 (Two-hybrid)

ESM2 similar proteins: A1A643, O08849, O08850, O14921, O15539, O35119, O43665, O46470, O54829, P34295, P41220, P49758, P49800, P49802, P49803, P49806, P49808, P49809, P79100, P97844, Q08116, Q09777, Q0P5H5, Q10955, Q2KHW7, Q2M5E4, Q3S853, Q3T0T8, Q4L0E8, Q5M8L6, Q62240, Q6DGI0, Q6RG78, Q864Z2, Q8K443, Q8VYB9, Q99PG4, Q9CQE5, Q9FLY5, Q9JHX0

Diamond homologs: A1A643, F1S668, O08773, O08774, O08849, O08850, O08899, O14921, O14924, O15169, O15492, O15539, O35625, O42400, O43566, O43665, O46469, O46470, O46471, O54828, O54829, O70239, O70240, O70521, O75916, O76081, O88566, O94810, P34295, P41220, P49758, P49795, P49796, P49797, P49798, P49799, P49800, P49802, P49803, P49804

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 47 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of the cornified envelope	14	36.2×	2e-17
Keratinization	18	29.5×	4e-21

GO biological processes:

GO term	Partners	Fold	FDR
keratinization	14	88.6×	2e-22

Disease & clinical

Clinical variants and AI predictions

ClinVar

20 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	18
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1015 predictions. Top by Δscore:

Variant	Effect	Δscore
6:153024307:AG:A	donor_gain	0.9900
6:153026447:CA:C	donor_gain	0.9900
6:153026448:ACTC:A	donor_loss	0.9900
6:153026449:C:CG	donor_loss	0.9900
6:153026450:TCAC:T	donor_loss	0.9900
6:153026452:A:AC	donor_gain	0.9900
6:153026453:C:A	donor_loss	0.9900
6:153026453:C:CC	donor_gain	0.9900
6:153026453:CCATT:C	donor_gain	0.9900
6:153026478:T:A	donor_gain	0.9900
6:153026539:TGAGG:T	acceptor_gain	0.9900
6:153026540:GAGG:G	acceptor_gain	0.9900
6:153026541:AGGCT:A	acceptor_loss	0.9900
6:153026542:GG:G	acceptor_gain	0.9900
6:153026542:GGCTG:G	acceptor_loss	0.9900
6:153026544:C:CC	acceptor_gain	0.9900
6:153026544:C:G	acceptor_loss	0.9900
6:153026545:T:A	acceptor_loss	0.9900
6:153026549:A:AC	acceptor_gain	0.9900
6:153011675:T:C	donor_gain	0.9800
6:153024261:CCT:C	donor_gain	0.9800
6:153024494:TGG:T	acceptor_gain	0.9800
6:153024497:C:CC	acceptor_gain	0.9800
6:153025863:T:TG	acceptor_gain	0.9800
6:153026446:ACAC:A	donor_loss	0.9800
6:153026541:AGG:A	acceptor_gain	0.9800
6:153026549:A:C	acceptor_gain	0.9800
6:153024303:T:TA	donor_gain	0.9700
6:153024492:TTTGG:T	acceptor_gain	0.9700
6:153024493:TTGG:T	acceptor_gain	0.9700

AlphaMissense

1401 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:153011637:A:C	F190L	1.000
6:153011637:A:T	F190L	1.000
6:153011638:A:G	F190S	1.000
6:153011639:A:G	F190L	1.000
6:153011640:C:A	R189S	1.000
6:153011640:C:G	R189S	1.000
6:153011641:C:A	R189M	1.000
6:153011641:C:G	R189T	1.000
6:153011642:T:A	R189W	1.000
6:153011642:T:C	R189G	1.000
6:153011650:G:A	S186F	1.000
6:153011652:A:C	D185E	1.000
6:153011652:A:T	D185E	1.000
6:153011653:T:A	D185V	1.000
6:153011653:T:C	D185G	1.000
6:153011653:T:G	D185A	1.000
6:153011654:C:A	D185Y	1.000
6:153011654:C:G	D185H	1.000
6:153011654:C:T	D185N	1.000
6:153011655:T:A	R184S	1.000
6:153011655:T:G	R184S	1.000
6:153011656:C:A	R184I	1.000
6:153011656:C:G	R184T	1.000
6:153011661:C:A	M182I	1.000
6:153011661:C:G	M182I	1.000
6:153011661:C:T	M182I	1.000
6:153011662:A:C	M182R	1.000
6:153011662:A:G	M182T	1.000
6:153011662:A:T	M182K	1.000
6:153011664:T:A	L181F	1.000

dbSNP variants (sampled 300 via entrez): RS1000005373 (6:153008883 A>G), RS1000037762 (6:153040842 T>C), RS1000050965 (6:153054650 C>T), RS1000054607 (6:153009291 C>G), RS1000064636 (6:153084328 A>G,T), RS1000069381 (6:153129791 T>A), RS1000093101 (6:153038052 A>G), RS1000112380 (6:153088852 A>G), RS1000167003 (6:153047537 C>T), RS1000260174 (6:153048654 T>C), RS1000297139 (6:153090659 C>T), RS1000298063 (6:153132423 T>C), RS1000302394 (6:153123847 T>C), RS1000311807 (6:153040934 G>C,T), RS1000352962 (6:153015949 A>G)

Disease associations

OMIM: gene MIM:607191 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

19 associations (top):

Study	Trait	p-value
GCST001942_11	Prostate cancer	4.000000e-18
GCST003121_10	Alcohol dependence	5.000000e-06
GCST003127_8	Lipoprotein (a) levels	1.000000e-09
GCST004904_34	Body mass index	3.000000e-11
GCST004904_56	Body mass index	5.000000e-09
GCST006627_66	Diastolic blood pressure	1.000000e-09
GCST007325_198	General risk tolerance (MTAG)	2.000000e-08
GCST007565_105	Morning person	3.000000e-15
GCST009083_1	Bacterial meningitis	7.000000e-08
GCST009086_1	Pneumococcal meningitis	4.000000e-07
GCST009151_4	High density lipoprotein cholesterol levels	7.000000e-14
GCST009181_9	Cuneus cortex volume	7.000000e-06
GCST010241_403	Apolipoprotein A1 levels	1.000000e-10
GCST010242_13	HDL cholesterol levels	4.000000e-17
GCST010244_120	Triglyceride levels	1.000000e-08
GCST010988_379	Adult body size	4.000000e-11
GCST011320_12	Type 2 diabetes or prostate cancer (pleiotropy)	1.000000e-15
GCST90020025_549	Waist-to-hip ratio adjusted for BMI	5.000000e-09
GCST90020027_1026	Waist-hip index	6.000000e-09

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0006925	lipoprotein A measurement
EFO:0004340	body mass index
EFO:0006336	diastolic blood pressure
EFO:0008579	risk-taking behaviour
EFO:0008328	chronotype measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004530	triglyceride measurement
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295974 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 12,011 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL417799	SANGUINARIUM	2	8,822
CHEMBL490129	SANGUINARIUM CHLORIDE	2	3,189

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs672170	Efficacy	3	antidepressants	Major Depressive Disorder

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs672170	RGS17	3	0.00	1	antidepressants

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — RZ family

Most potent curated ligand interactions (8 total), top 8:

Ligand	Action	Affinity	Parameter
compound I [PMID: 29351497]	Inhibition	5.02	pIC50
celastrol	Inhibition	4.98	pIC50
compound III [PMID: 29351497]	Inhibition	4.84	pIC50
compound V [PMID: 29351497]	Inhibition	4.84	pIC50
compound II [PMID: 29351497]	Inhibition	4.72	pIC50
compound IV [PMID: 29351497]	Inhibition	4.51	pIC50
irigenol	Inhibition	4.33	pIC50
pseudochelerythrine	Inhibition	4.14	pIC50

ChEMBL bioactivities

8 potent at pChembl≥5 of 19 total, top 8 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.37	IC50	423.2	nM	IRIGENOL
6.15	Kd	714	nM	IRIGENOL
6.00	Kd	1000	nM	SANGUINARIUM
5.99	Kd	1020	nM	SANGUINARIUM CHLORIDE
5.86	IC50	1386	nM	SANGUINARIUM CHLORIDE
5.22	IC50	6000	nM	CELASTROL
5.20	IC50	6359	nM	CELASTROL
5.00	IC50	1e+04	nM	GAMBOGIC ACID

PubChem BioAssay actives

3 with measured affinity, of 30 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
24-methyl-5,7,18,20-tetraoxa-24-azoniahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-1(24),2,4(8),9,11,13,15,17(21),22-nonaene	1377216: Binding affinity to RGS17 (unknown origin) by ITC method	kd	1.0000	uM
(2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid	1377215: Inhibition of RGS17 (unknown origin) GAP activity in presence of GTP by malachite green dye based assay	ic50	6.0000	uM
(Z)-4-[(1S,2S,8R,17S,19R)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.02,15.02,19.04,13.06,11]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid	1377215: Inhibition of RGS17 (unknown origin) GAP activity in presence of GTP by malachite green dye based assay	ic50	10.0000	uM

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression, increases methylation	3
Particulate Matter	increases abundance, affects cotreatment, increases expression, decreases expression	3
Benzo(a)pyrene	affects methylation, increases methylation	2
Cisplatin	increases response to substance, affects cotreatment, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
terbufos	increases methylation	1
trichostatin A	increases expression, decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
aflatoxin B2	affects methylation	1
hydroquinone	increases expression	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
Docetaxel	increases response to substance	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Fulvestrant	decreases methylation	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects methylation	1
Vehicle Emissions	increases methylation	1
Calcitriol	increases expression, affects cotreatment	1
Diazinon	decreases methylation	1

ChEMBL screening assays

20 unique, capped per target: 20 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4191647	Binding	Inhibition of RGS17 (unknown origin) GAP activity in presence of GTP by malachite green dye based assay	Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines. — J Nat Prod

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.